文献速递角膜与眼表疾病

耐甲氧西林金黄色葡萄球菌角膜炎:初始治疗、危险因素、临床特征与治疗结局

Methicillin-Resistant Staphylococcus aureus Keratitis: Initial Treatment, Risk Factors, Clinical Features, and Treatment Outcomes.
PubMed 文献 · Am J Ophthalmol · 2020-03-21

该回顾性介入性病例系列分析了52眼培养证实的MRSA角膜炎,发现常见危险因素包括眼部手术史、局部糖皮质激素使用和干眼,全身疾病负担高;17.3%发生穿孔需手术干预,视力结局较差;第四代氟喹诺酮与强化万古霉素治疗在最终视力、疗程和手术需求上无差异。

要点

  • MRSA角膜炎常需手术干预,17.3%患眼发生穿孔,视力结局较差。
  • 常见危险因素包括眼部手术史、局部糖皮质激素使用和干眼。
  • 第四代氟喹诺酮与强化万古霉素治疗结局相当,但后者溃疡更重。

核心结论

  • MRSA角膜炎呈暴发性病程,常需手术管理且视力结局差。
  • 眼表条件差、局部糖皮质激素使用、既往眼部手术和/或高全身疾病负担是常见危险因素。
  • 本研究中氟喹诺酮治疗与强化万古霉素治疗结局相当,但强化万古霉素组就诊时溃疡更严重。

研究设计与样本

  • 回顾性介入性病例系列,纳入匹兹堡大学医学中心诊断和治疗的52例(52眼)培养证实的MRSA角膜炎病例。

主要发现

  • 平均年龄66.6±19.2岁,中位随访147天。
  • 最常见危险因素为眼部手术史(62.5%)、局部糖皮质激素使用(35.4%)和干眼综合征(37.5%),全身疾病负担高(95.8%)。
  • 平均初诊logMAR视力1.7±0.8,平均最终logMAR视力1.2+1.0。
  • 17.3%患眼发生穿孔,13.5%需睑缘缝合术,5.8%需穿透性角膜移植术,1眼行眼球摘除。
  • 第四代氟喹诺酮与强化万古霉素治疗在最终视力、治疗时长或手术需求上无差异。

关键数值与推荐

  • 初始抗生素治疗:20.8%单用莫西沙星,20.8%联合强化头孢唑林和强化妥布霉素,12.5%联合强化万古霉素和强化妥布霉素。

临床怎么用

  • 对具有眼部手术史、局部糖皮质激素使用、干眼或高全身疾病负担的角膜炎患者,应警惕MRSA感染可能。
  • MRSA角膜炎需密切监测并发症,必要时及时手术干预。
  • 氟喹诺酮可作为治疗选择之一,但需注意强化万古霉素组就诊时溃疡更严重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the clinical characteristics, management choices, and outcomes of cases of methicillin-resistant Staphylococcus aureus (MRSA) keratitis. DESIGN: Retrospective interventional case series. METHODS: Fifty-two culture-proven (52 eyes) cases of MRSA keratitis diagnosed and treated at the University of Pittsburgh Medical Center were identified and reviewed. RESULTS: The mean age was 66.6 ± 19.2 years with a median follow-up time of 147 days. The most prevalent risk factors included a history of ocular surgery (62.5%), topical corticosteroid use (35.4%), and dry eye syndrome (37.5%). There was a high burden of systemic disease (95.8%). The average presenting logarithm of minimal angle of resolution visual acuity was 1.7 ± 0.8 and the average final logarithm of minimal angle of resolution visual acuity was 1.2 + 1.0. Initial antibiotic treatment varied, with 20.8% receiving moxifloxacin alone, 20.8% receiving fortified cefazolin and fortified tobramycin together, and 12.5% receiving fortified vancomycin and fortified tobramycin, although other antibiotics were used during treatment if warranted. Surgical management was often required as 17.3% of eyes perforated: 13.5% required tarsorrhaphy, 5.8% required penetrating keratoplasty, and 1 eye was enucleated. When patients treated with fourth-generation fluoroquinolones were compared with those treated with fortified vancomycin, no difference in final visual acuity, treatment duration, or need for surgery was found. CONCLUSION: MRSA causes fulminant keratitis often requiring surgical management with poor visual acuity outcomes. Poor ocular surface, topical corticosteroid use, previous ocular surgery, and/or a high burden of systemic disease were identified as common risk factors. Patients treated with fluoroquinolones in our study had comparable outcomes to those treated with fortified vancomycin; however, those treated with fortified vancomycin tended to have more severe ulcers at presentation.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Durrani AF, Atta S, Bhat AK, et al. Methicillin-Resistant Staphylococcus aureus Keratitis: Initial Treatment, Risk Factors, Clinical Features, and Treatment Outcomes. Am J Ophthalmol. 2020. PMID: 32209347. doi:10.1016/j.ajo.2020.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。